吉西他滨联合腹腔热灌注顺铂治疗复发性卵巢癌的临床观察

目的：探讨吉西他滨静脉化疗联合顺铂高精度持续循环腹腔热灌注化疗对复发性卵巢癌的临床疗效和安全性。方法55例复发性卵巢癌患者分为2组，观察组28例予顺铂高精度持续循环腹腔热灌注化疗，第5天予吉西他滨＋卡铂静脉化疗；对照组27例仅予单纯静脉化疗，21 d为1周期。比较2组肿瘤控制情况、腹腔积液控制情况、KPS评分及毒副反应。结果观察组和对照组患者治疗3周期后的肿瘤控制有效率分别为82.1%、44.4%（P〈0.05）；2组腹腔积液控制有效率分别为87.0%、45.0%（P〈0.05）；2组KPS评分改善率分别为85.7%、51.9%（P〈0.05）。2组患者的毒副反应均可耐受。结论吉西他滨联合顺铂高精度持续循环腹腔热灌注化疗治疗复发性卵巢癌不仅能提高肿瘤控制率，减少腹腔积液，还能显著改善患者生活质量，安全性高。

Treatment of Recurrent Ovarian Cancer by Gemcitabine plus High Accurate Continuous Circulation Intraperitoneal Hyperthermic Chemotherapy of Cisplatin

Objective To investigate the clinical efficacy and safety of gemcitabine plus high accurate continuous circulation intraperitoneal hyperthermic chemotherapy of cisplatin for recurrent ovarian cancer. Methods All the 55 patients with recurrent ovarian cancer were divided into 2 groups,28 patients of the observation group received the high accurate continuous circulation intraperitoneal hyperthermic chemotherapy of cisplatin,and then with intrave-nous chemotherapy of gemcitabine and carboplatin on the fifth day;27 patients of the control group received only the intravenous chemotherapy. 21 days were 1 cycle. And then the tumor control rate,the ascitic fluid control rate,KPS scores,and the toxicities were compared between the two groups. Results After 3 circles of treatment,the tumor control effective rates were 82. 1% and 44. 4% in the observation group and the control group respectively（ P〈0. 05）. The ascitic fluid control effective rates were 87. 0% and 45. 0% respectively（P〈0. 05）. The KPS score improvement rates were 85. 7% and 51. 9% in the observation group and the control group（P〈0. 05）. The toxici-ties were tolerable for both the two groups. Conclusion Gemcitabine plus high accurate continuous circulation in-traperitoneal hyperthermic chemotherapy of cisplatin can enhance the tumor control rate,reduce the ascitic fluid,sig-nificantly improve the quality of life,and has good safety for recurrent ovarian cancer.